Helius Medical Technologies, Inc. to Participate in Noble Capital Markets’ Virtual Road Show Series
June 08 2021 - 4:05PM
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM),
(“Helius” or the “Company”), a neurotech company focused on
neurological wellness, today announced its participation in Noble
Capital Markets’ Virtual Road Show Series, presented by
Channelchek, which is scheduled for Thursday, June 10, 2021.
The event will feature a corporate presentation followed by a
Q&A session proctored by Noble Capital Markets’ Senior Research
Analyst, Joe Gomes, featuring questions submitted by the
audience.
The live webcast of the event is scheduled for June 10, 2021, at
1:00 p.m. Eastern. Register for the webcast here. A recording will
be available on Channelchek and under the ‘Events’ section of the
Helius Medical Technologies investor relations website at
https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on
neurological wellness. The Company’s purpose is to develop, license
and acquire unique and non-invasive platform technologies that
amplify the brain’s ability to heal itself. The Company’s first
commercial product is the Portable Neuromodulation Stimulator
(PoNSTM). For more information,
visit www.heliusmedical.com.
About the
PoNSTM Device and PoNS
TreatmentTM
The Portable Neuromodulation Stimulator (PoNSTM)
is an innovative non-surgical device, inclusive of a controller and
mouthpiece, which delivers electrical stimulation to the surface of
the tongue to provide treatment of gait deficit. The PoNS device is
indicated for use in the United States as a short term treatment of
gait deficit due to mild-to-moderate symptoms from multiple
sclerosis (“MS”) and is to be used as an adjunct to a supervised
therapeutic exercise program in patients 22 years of age and over
by prescription only. It is authorized for sale in Canada as a
class II, non-implantable, medical device intended as a short term
treatment (14 weeks) of gait deficit due to mild and moderate
symptoms from MS, and chronic balance deficit due to
mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used
in conjunction with physical therapy. The PoNSTM is an
investigational medical device in the European Union (“EU”) and
Australia (“AUS”). It is currently under premarket review by the
AUS Therapeutic Goods Administration.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies,
Inc.Jack Powell, Vice
Presidentinvestorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2023 to Apr 2024